Bear,

I think maybe this:

"If BETonMACE succeeds, it will do what no DPP4 inhibitor, SGLT2 inhibitor or GLP1-R agonist has been able to do........ reduce time to subsequent 3-point MACE in patients experiencing a recent ACS event. That would be huge."

is not the frontier we're aiming for.  How about:" increase the time to subsequent 3-point MACE in patients experiencing a recent ACS event."

LOL - Merry Christmas to all,

Jupe